Clinical Trial Update: Evaluating the Effect of Aliskiren Versus HCTZ on Coronary Flow Reserve in Hypertensive Type II Diabetics [Phase 4]

View source ↗

Summary

A Phase 4 trial evaluating aliskiren versus hydrochlorothiazide in hypertensive patients with type 2 diabetes has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertension
• Type 2 Diabetes Mellitus

Drugs mentioned

• Aliskiren (Aliskiren)
• HYDROCHLOROTHIAZIDE (hydrochlorothiazide)

Snippet

Sponsor: Corewell Health East | Conditions: Hypertension, Diabetes Type 2 | Phase 4 | Status: WITHDRAWN